UNDER EMBARGO UNTIL 12 PM GMT MONDAY 4 FEBRUARY 2013

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A has been published in The Lancet

• Vaccine candidate was generally well tolerated, meeting the study's primary objective of safety
• Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG

Read the full Press Release